Allarity Therapeutics(US:ALLR) GlobeNewswire News Room·2024-09-30 22:34Core Viewpoint - Rosen Law Firm is reminding investors who purchased Allarity Therapeutics, Inc. securities between May 17, 2022, and July 19, 2024, of the upcoming lead plaintiff deadline on November 12, 2024, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Allarity securities during the specified class period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2]. - To serve as lead plaintiff, individuals must file a motion with the court by November 12, 2024 [2]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for its success in this area [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3]. Group 3: Case Allegations - The lawsuit alleges that Allarity and its former officers made false statements regarding the regulatory prospects of Dovitinib, a drug candidate for renal cell carcinoma [4]. - It is claimed that the defendants engaged in improper conduct related to the drug's new drug application and premarket approval application, leading to increased regulatory scrutiny and potential legal repercussions [4]. - The lawsuit asserts that Allarity downplayed the likelihood of enforcement actions following an investigation into these matters, resulting in materially false and misleading public statements [4].